LAG3 and melanoma: Moreover, the same ligand demonstrated to be more effective in suppressing B16 melanoma growth than the antibody-based blockade of lymphocyte activation gene-3 (LAG-3, which is downregulated via GSK3 inhibition), and showed to potentiate the effect of an anti-LAG-3 therapy in terms of complete clearance of tumor mass in mice, outperforming the combination of anti-LAG-3 and anti PD-1 antibodies [16].